5 Most Undervalued Biotech Stocks to Buy Right Now

4. Royalty Pharma Plc (NASDAQ:RPRX)

Royalty Pharma Plc (NASDAQ:RPRX) is one of the most undervalued biotech stocks to buy right now. Royalty Pharma Plc (NASDAQ:RPRX) announced on April 17 that its board of directors approved the payment of a dividend for the second quarter of 2026 of $0.235 per Class A ordinary share. Management stated that the dividend will be paid on June 10, 2026, to shareholders of record at the close of business on May 15, 2026. In a separate development, Morgan Stanley lifted the price target on Royalty Pharma Plc (NASDAQ:RPRX) to $63 from $61 on April 10, reiterating an Overweight rating on the shares and adjusting models among the stocks under its biopharma coverage for IQVIA trends as well as intra-quarter updates ahead of the group’s fiscal Q1 earnings reports.

Royalty Pharma Plc (NASDAQ:RPRX) also announced on March 30 a research and development (R&D) co-funding agreement with Johnson & Johnson for a total of $500 million in 2026 and 2027, aimed at advancing the development of JNJ-4804, an investigational medicine for autoimmune diseases.

Royalty Pharma Plc (NASDAQ:RPRX) funds innovation in the biopharmaceutical industry and buys biopharmaceutical royalties. It collaborates with innovators from research hospitals, non-profits, and academic institutions through small and mid-cap biotech companies to global pharma companies. The company funds innovation in the industry both directly, by partnering with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly, by acquiring existing royalties from the original innovators.